본문 영역으로 바로가기

업계소식

Could Roche's lymphoma drug Columvi be a rival against Novartis' Kymriah...

조회수 106

[ 기사일자 ]
Thu, 04 Jan 2024 11:16:00 +0900

[ 기사내용 ]
At one year and six months of treatment, the primary endpoint, complete response (CR), was 60... higher CR rate for Lunsumio than patients treated with the PI3K inhibitor Aliqopa (copanlisib...

[ 원문기사 상세보기 ]
https://www.koreabiomed.com/news/articleView.html?idxno=22955

목록보기

TOP